PMGC Holdings Inc. ELAB 深 沪
等待开盘 04-03 09:30:00 美东时间
5.72
-8.280
-59.14%
华盛通- 最 高14.00
- 今 开5.23
- 成交量 2407.83万股
- 最 低 0.6613
- 昨 收 14.00
- 总市值 0
- 52周最高 14.00
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.6613
- 委 比 78.95%
- 总股本 --
- 历史最高 14.00
- 量 比 0.77
- 振 幅 95.28%
- 历史最低 0.0125
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasdaq Down 1%; US Initial Jobless Claims Fall
US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer discretionary stocks fell. US jobless claims declined.
04-02 22:44
Dow Gains 200 Points; Bullfrog AI Shares Jump
US stocks up, Dow gains 200 points, NASDAQ slightly up. Utilities rise, industrials fall. Americas Gold and Silver Corp shares down 13% after earnings.
03-30 22:25
Market-Moving News for March 24th
NTGR: 16% | Netgear shares are trading higher after the FCC added internet routers made in foreign countries to its covered list of prohibited products. ELAB: 55% | PMGC Holdings' Subsidiary, SVM
03-24 19:25
NorthStrive Biosciences Executes Definitive, Exclusive License Agreement With Modulant Biosciences
NorthStrive Biosciences Inc. ("NorthStrive"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), today announced that it has executed a definitive, exclusive license
02-11 20:33
PMGC's AGA Precision Systems Unit Achieves AS9100 Certification
PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC," the "Company," "we," or "our") today announced that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA"), successfully achieved AS9100 certification, the globally
2025-12-22 20:38
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
PMGC Capital urge Alaunos Therapeutics to accept a Wall Street bank-backed financing offer, calling it a strategic opportunity to create value for shareholders.
2025-06-18 13:52
Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases
Northstrive Biosciences and Yuva Biosciences have launched Phase II of their AI Development Program, utilizing MitoNova™ to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases. This collaboration aims to develop innovative pharmaceutical treatments for related conditions.
2025-06-17 13:04
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years
PMGC Holdings Inc. has signed a non-binding Letter of Intent (LOI) to acquire a California-based CNC machining company specializing in precision milling, turning, mold manufacturing, and exotic metals for aerospace, defense, and industrial markets, aligning with its strategic focus.
2025-06-16 12:00
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company
PMGC Holdings Inc. has signed a non-binding Letter of Intent to acquire a U.S.-based electronics contract manufacturing company with over 40 years of history, specializing in high-precision electrical and mechanical assembly. This is the company's second acquisition since April, reflecting its active M&A strategy. The target company generated $699,000 in revenue and $173,000 in adjusted EBITDA in 2024.
2025-06-09 12:00
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia
Northstrive Biosciences Inc. announces completion of Phase I research for its first-in-class oral myostatin-engineered probiotic, EL-22, targeting muscle-wasting conditions, including GLP-1-associated atrophy. Key findings include strong preclinical rationale and unique oral vaccine approach. The company plans Phase 2 trial for GLP-1 users and regulatory engagement for IND filing.
2025-05-22 12:16
